Evert Jan Van Limbergen

Evert Jan Van Limbergen

Auto-generated profile, based on publicly available information

Evert Jan Van Limbergen

Department of Radiation Oncology (MAASTRO), GROW Research Institute for Oncology and Reproduction, Maastricht University Medical Center, Maastricht, the Netherlands

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 May 2020 in Molecular Oncology
Verified
Journal Article
Open access
PDF file
RLRelinde I. Y. Lieverse
Relinde I. Y. Lieverse
DMDamiënne Marcus
Damiënne Marcus
AWAlexander M. A. van der Wiel
Alexander M. A. van der Wiel
ELEvert J. Van Limbergen
Evert J. Van Limbergen
JTJan Theys
Jan Theys
Ludwig DuboisLudwig Dubois
Ludwig Dubois
The extracellular matrix protein fibronectin contains a domain that is rarely found in healthy adults and is almost exclusively expressed by newly formed blood vessels in tumours, particularly in solid tumours, different types of lymphoma and some leukaemias. This domain, called the extra domain B (ED‐B), thus has broad therapeutic potential. The antibody L19 has been developed to specifically target ED‐B and has shown therapeutic potential when combined with cytokines, such as IL‐2. In this review article, we discuss the preclinical research and clinical trials that highlight the potential of ED‐B targeting for the imaging and treatment of various types of cancer. ED‐B‐centred studies also highlight how proper patient stratification is of utmost importance for the successful implementation of novel antibody‐based targeted therapies.

1 April 2021 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Open access
ELEvert Jan Van Limbergen
Evert Jan Van Limbergen
AHAnn Hoeben
Ann Hoeben
RLRelinde I.Y. Lieverse
Relinde I.Y. Lieverse
RHRuud Houben
Ruud Houben
COChantal Overhof
Chantal Overhof
Philippe LambinPhilippe Lambin
Philippe Lambin
The immunocytokine L19-IL2 delivers interleukin-2 to the tumor by exploiting the selective L19-dependent binding of extradomain B of fibronectin on tumor blood vessels. In preclinical models, L19-IL2 has been shown to enhance the local and abscopal effects of radiation therapy. The clinical safety of L19-IL2 monotherapy has been established previously. In this study, the safety and tolerability of L19-IL2 after stereotactic body radiation therapy (SBRT) was assessed. Patients with oligometastatic solid tumors received radical SBRT to all visible metastases. Within 1 week after SBRT, intravenous L19-IL2 using a 3 + 3 dose escalation design was administered. Safety and tolerability were analyzed as the primary endpoint using the Common Terminology Criteria for Adverse Events 4.03 scoring system, with progression-free and overall survival as secondary endpoints. A total of 6 patients in 2 L19-IL2 dose levels were included. The 15 million International Units (Mio IU) dose level was well tolerated with no dose-limiting toxicity. The most frequently reported adverse events were chills, noninfectious fever, fatigue, edema, erythema, pruritus, nausea/vomiting, and cough and dyspnea. Blood analysis revealed abnormalities in liver function tests, anemia, hypoalbuminemia, and hypokalemia. At the second dose level (ie, 22.5 Mio IU), which is the recommended dose for L19-IL2 monotherapy, all 3 included patients experienced dose-limiting toxicity but recovered without sequelae. We documented 2 long-term progression-free responders, both having non-small cell lung cancer as primary tumor. Based on the results of this phase 1 clinical trial, the recommended phase 2 dose for SBRT combined with L19-IL2 is 15 Mio IU. The therapeutic efficacy of this combination is currently being evaluated in the multicentric EU-funded phase 2 clinical trial, ImmunoSABR.

1 March 2021 in Clinical and Translational Radiation Oncology
Verified
Journal Article
Open access
BVBen Vanneste
Ben Vanneste
ELEvert J. Van Limbergen
Evert J. Van Limbergen
TMTom Marcelissen
Tom Marcelissen
KRKobe Reynders
Kobe Reynders
JMJarno Melenhorst
Jarno Melenhorst
LLLudy Lutgens
Ludy Lutgens
Prostate cancer radiotherapy (RT) in patients with (active) inflammatory bowel disease (IBD) remains controversial. We hypothesized that RT in combination with a biodegradable prostate-rectum spacer balloon implantation, might be a safe treatment approach with acceptable toxicities for these high risk for rectal toxicity patients. We report on a small prospective mono-centric series of 8 patients with all-risk prostate cancer with the comorbidity of an IBD. Four patients had Crohn’s disease and 4 patients had ulcerative colitis. One out of four had an active status of IBD. All patients were intended to be treated with curative high-dose RT: 5 patients were treated with external beam RT (70 Gray (Gy) in 28 fractions), and 3 patients were treated with 125I-implant (145 Gy). Toxicities were scored according to the CTCAE v4.03: acute side effects occur up to 3 months after RT, and late side effects start after 3 months. Median follow-up was 13 months (range: 3–42 months). Only one acute grade 2 gastro-intestinal (GI) toxicity was observed: an increased diarrhea (4–6 above baseline) during RT, which resolved completely 6 weeks after treatment. No late grade 3 or more GI toxicity was reported, and no acute and late grade ≥2 genitourinary toxicity events were observed. Prostate cancer patients with IBD are a challenge to treat with RT. Our results suggest that RT in combination with a balloon implant in selective patients with (active) IBD may be promising, however additional validation is needed.

4 July 2024 in Brachytherapy
Verified
Journal Article
Closed access
DCDries Colson
Dries Colson
BYBurak Yalvac
Burak Yalvac
JWJan Weterings
Jan Weterings
AVAn-Sofie Verrijssen
An-Sofie Verrijssen
PHPaul van Haaren
Paul van Haaren
BRBrigitte RENIERS
Brigitte RENIERS

17 April 2026 in Physics in Medicine & Biology
Verified
Journal Article
Closed access
PDF file
DCDries Colson
Dries Colson
FVFemke Vaassen
Femke Vaassen
BYBurak Yalvac
Burak Yalvac
JWJan Weterings
Jan Weterings
VPvan Haaren Paul
van Haaren Paul
BRBrigitte RENIERS
Brigitte RENIERS
Objective. To investigate the evolution of beam quality in the Papillon+ contact x-ray therapy device and its dosimetric impact, a fast and straightforward beam quality index (QI) measurement method was proposed and validated. Additionally, the dosimetric consequences of tumour intrusion into the applicator tube were examined through Monte Carlo (MC) simulations and, for the first time, direct in-applicator dose measurements. Approach. QI measurements were performed every four weeks from mid-2022. Half-value layer (HVL) and depth-dose profile measurements in a plastic water low energy range phantom were conducted twice, with a two-year interval. Dose distributions for tumour intrusion scenarios (2.5–10 mm) were assessed using MC simulations and Gafchromic film measurements inside the applicator tube. Gross tumour volume (GTV) dose calculations (physical and EQD2) were performed for varying tumour thicknesses, intrusion depths, and diameters. Main results. All methods consistently demonstrated progressive beam hardening over time, with the HVL increasing from 0.77 mm Al to 0.93 mm Al. This spectral shift, attributed to x-ray tube ageing and radiation-induced material changes, was reversibly corrected after service replacement of the flattening filter, restoring the soft spectrum (HVL ≈ 0.69 mm Al). Tumour intrusion produced the strongest dosimetric effect, with surface dose increases up to 2.4-fold at 10 mm intrusion, exceeding MC predictions. GTV D90 decreased with tumour thickness but increased sharply with intrusion depth, whereas tumour diameter and surrounding medium had a negligible impact. Significance. This work highlights the importance of systematic beam quality follow-up in contact x-ray brachytherapy systems. Routine QI monitoring, together with well-defined beam-quality specifications and action limits, enables early detection of deviations, timely maintenance, and sustained compliance of the delivered beam quality in clinical practice. Tumour positioning relative to and protrusion into the applicator remains the dominant factor affecting dose distribution, underscoring the need for precise clinical setup and ongoing device characterisation to ensure clinical accuracy and patient safety.